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Background: Tobramycin, used in the treatment of infections caused by Gram-negative bacteria, requires therapeutic drug monitoring
(TDM) due to its narrow therapeutic index. The collection of blood for these assays may cause pain and trauma to the child and/or be difficult
because of limited access to appropriate blood vessels. We undertook an evaluation of the role of saliva concentrations in the TDM of once-
daily tobramycin therapy in patients with cystic fibrosis.
Methods: Fourteen patients (mean age 15 years) with cystic fibrosis were enrolled at Women’s and Children’s Hospital, Adelaide
(WCH). All patients received once-daily dose of intravenous tobramycin for 2–3 weeks and had plasma levels measured once a week.
At the same time of blood sampling at 1 and 6 h after initiation of tobramycin infusion, the patients also provided saliva samples. For
collection of saliva, the SalivetteR (Sarstedt Laboratories) system was used which was developed specifically for saliva sampling.
Concentrations in blood and saliva were measured by the Beckman Synchron CXR system, which is utilized for routine assays of
plasma tobramycin.
Results and conclusion: Tobramycin could not be detected in saliva within the first 6 h after a once-daily dosing. Therefore, plasma cannot
be substituted with saliva for the TDM of tobramycin using the clinical routines at WCH.
D 2004 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
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Cystic fibrosis is a serious genetically inherited multi-
system disease. Chronic respiratory infection caused by
Pseudomonas aeruginosa is the principal cause of morbid-
ity and mortality in patients with cystic fibrosis [1].
Aminoglycosides play a central role in the medical
management of P. aeruginosa. Their success and continuing
use can be attributed to various factors including rapid
concentration-dependent bacterial effect, synergism with h-
lactam antibiotics, clinical effectiveness, a low rate of true
resistance and a low cost [2].1569-1993/$ - see front matter D 2004 Published by Elsevier B.V. on behalf of E
doi:10.1016/j.jcf.2004.08.003
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E-mail address: coulthardk@wch.sa.gov.au (K. Coulthard).Aminoglycosides are among the most potent but
potentially toxic antibiotics, and thus therapeutic drug
monitoring has become routine for administration of
aminoglycosides to optimise their clinical efficacy and
minimize their toxicity [3]. It has been demonstrated that
once-daily aminoglycoside administration is effective,
probably due to a prolonged post-antibiotic effect on
Gram-negative organisms and concentration-dependent kill-
ing [4].
Although blood is commonly used for therapeutic drug
monitoring, during the last two decades there has been
great interest in non-invasive methods [5]. Many inves-
tigations have been performed using saliva as a substitute
for blood in therapeutic drug monitoring. Berkovitch et
al. [6] demonstrated a correlation between plasma and
saliva concentration of gentamicin 72 h after once-daily
dosing of gentamicin administered intravenously indicat-3 (2004) 249–251uropean Cystic Fibrosis Society.
Table 1
Patient characteristics and tobramycin concentrations in plasma and saliva
Mean (FS.D.) Range
Number of patients 14
Gender (F/M) 3/11
Age (years) 15F2.0 11–17
Weight (kg) 54.9F17.4 31.70–90.02
Height (cm) 163.0F14.3 140.9–192.5
Daily dose (mg) tobramycin 505F136.3 320–800
Plasma sample, 1 h (Ag/mL) 22.5F3.1 17.4–27.6
Plasma sample, 6 h (Ag/mL) 3.7F1.0 2.0–5.7
Saliva sample, 1 h (Ag/mL) b1.0
Saliva sample, 6 h (Ag/mL) b1.0
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monitoring.
Our aim was to evaluate the use of saliva in children
receiving tobramycin once daily instead of plasma for
our routine dose adjustment using a pharmacokinetic
programme.2. Patients and methods
The Women’s and Children’s Hospital Research Ethics
Committee approved the study and informed consent was
obtained from all patients or parents. All children were
treated for P. aeruginosa infection with intravenous
tobramycin at a starting dose of 10 mg/kg/day for 2–3
weeks. The dose was individually adjusted according to
plasma levels 1 and 6 h after dosing using a pharmacoki-
netic programme. Plasma levels were measured once a
week. Two saliva samples and two blood samples from each
of the 14 patients (mean age 15 years) were available for
analysis. The saliva samples were collected and prepared for
assay by the SalivetteR (Sarstedt Laboratories) system; a
system especially developed for saliva sampling.
2.1. Tobramycin assay
Analyses of tobramycin concentrations were performed
using the Beckman Synchron CXR Systems via a particle-
enhanced turbidimetric inhibition immunoassay method.
Total (bound plus free) drug concentrations in saliva and
plasma were measured. This assay has coefficients of
variation of 4% and 2.5% at concentrations of 2 and 11.3
Ag/mL, respectively. The saliva was centrifuged at 4000g
for 7 min. The analytical range of the system was 1.0–12.0
Ag/mL [7]. The recovery of tobramycin from a SalivetteR
spiked with tobramycin was found to be 68–110% within
this concentration interval.3. Results
Plasma tobramycin concentrations ranged from 17.4–
27.6 Ag/mL at 1 h to 2.0–5.7 Ag/mL for the 6-h sample.Saliva tobramycin concentrations were all below the
lower limit of detection of the assay (b1.0 Ag/mL)
(Table 1).4. Discussion
This study finds that tobramycin does not distribute into
saliva in quantifiable amounts, using the Beckman Syn-
chron CXR Systems, when tobramycin is dosed once-daily
and measured 1 and 6 h after dosing. Six of the 14 patients
had received more than seven doses, producing plasma
levels N17.4 Ag/mL at 1 h and N2.0 Ag/mL at 6 h after a 15-
min infusion. Although the distribution of tobramycin is
probably not complete after 1 h, the calculated elimination
half-life of 1.9F0.3 h is in accordance with the literature [8].
Saliva tobramycin concentrations in these patients were
below assay range.
The apparent inability of tobramycin to penetrate into
saliva suggested by this study supports the findings of
Mahmod et al. [9] and Hendeles et al. [10]. On the other
hand, Berkovitch et al. [6,11] used a very sensitive assay
(0.05 nmol/L) [11] and showed a correlation between
serum and saliva gentamicin concentration 72 h after
initiation of a once-daily dosing. They did not find the
same correlation after thrice-daily dosing. They suggest
that the physicochemical characteristics of aminoglyco-
sides, which are hydrophilic compounds with a positive
charge at physiologic pH, are responsible for a slow
distribution into many body fluids except for blood and
urine. The correlation they observed could be due to the
once-daily dosing high peak concentration combined with
the sufficient time for the aminoglycoside to equilibrate
with saliva.
In conclusion, this study shows that tobramycin cannot
be quantitated in saliva at concentrations above 1 Ag/mL at
1 or 6 h after once-daily dosing. Plasma cannot be
substituted by saliva for the therapeutic drug monitoring
approach as practiced in this hospital.References
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